Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 136 от 222

Набира участници

An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects

Limb Fracture Bone Loss

Long bone defect (LBD) is defined as a focalized loss of bone tissue in any long bone of the upper or lower extremity. Long bone defects are a complex problem, that may arise as a complication of many different pathologies, such as trauma, tumors or infection. Whereas post-traumatic defects are the largest group. Reports estimate that there are almost 4 million bone grafting procedures worldwide per year. However, limb reconstruction in the context of a bony defect is challenging and up to date there is little evidence and treatment recommendations. In a multi-national approach, the aim of this project is to set up an international, multicenter registry to gather information and details on prevalence or incidence, current treatments, complications and outcome.

Начало: 03.07.2024 Край: 30.03.2029 Възраст: от 18 г.

Australia, Brazil, Chile +11 AO Innovation Translation Center NCT04112992

Набира участници Фаза 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Solid Tumors Neoplasms

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Начало: 02.07.2024 Край: 20.09.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +11 GlaxoSmithKline NCT06431594

Набира участници Фаза 1/2

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Systemic Sclerosis Scleroderma

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis

Начало: 02.07.2024 Край: 01.07.2029 Възраст: 18–75 г.

United States Cabaletta Bio NCT06328777

Набира участници Фаза 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic Nephropathies Primary Focal Segmental Glomerulosclerosis Minimal Change Disease Primary Immunoglobulin A Nephropathy +1

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.

Начало: 02.07.2024 Край: 01.06.2027 Възраст: 18–75 г. Лечение

Australia, India, Malaysia +4 Walden Biosciences NCT06466135

Набира участници

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

Cardiac Amyloidosis

Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography

Начало: 01.07.2024 Край: 02.02.2028 Възраст: от 80 г.

France Gérond'if NCT06427304

Набира участници Фаза 1

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.

Начало: 01.07.2024 Край: 30.03.2027 Възраст: от 18 г. Лечение

Australia Inimmune Corporation NCT06302426

Набира участници

NODE (groiN ultrasOunD cancEr)

Vulvar Cancer Stage Ib Vulvar Cancer Stage II Lymph Node Metastasis Groin Node +1

This study is an open label, prospective, experimental, randomised clinical trial. The primary aim of this study is to determine whether it is feasible to randomise vulvar cancer patients into one of two treatment arms:1) surgical groin node dissection (as delivered though either a sentinel node biopsy or inguinofemoral lymph node dissection (IFL), or 2) serial high-resolution bilateral groin ultrasound surveillance and clinical examination every 2 months for 12 months.

Начало: 01.07.2024 Край: 31.12.2027 Възраст: от 18 г. Друго

Australia Queensland Centre for Gynaecological Cancer NCT06264167

Набира участници Фаза 1

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Hepatocellular Carcinoma

This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Начало: 01.07.2024 Край: 31.05.2028 Възраст: от 18 г. Лечение

Australia, South Korea, Taiwan Myeloid Therapeutics NCT06478693

Набира участници Фаза 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Metastatic Solid Tumor Recurrent Solid Tumor Advanced Solid Tumor Urinary Bladder Neoplasm +10

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Начало: 01.07.2024 Край: 01.05.2027 Възраст: от 18 г. Лечение

Australia, China, France +5 Eli Lilly and Company NCT06465069

Набира участници Фаза 2

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Onychomycosis

The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis

Начало: 01.07.2024 Край: 30.01.2026 Възраст: 18–70 г. Лечение

New Zealand AmtixBio Co., Ltd. NCT06327295

Набира участници

Mechanistic Insights From Bronchoscopy Airway Samples

Asthma

The purpose of this study is to examine the mechanisms of asthma. The investigators are comparing the cells of individuals with and without asthma and looking at the roles various parts of the cell play in the production and secretion of mucus.

Начало: 01.07.2024 Край: 01.12.2028 Възраст: 18–70 г.

United States University of California, San Francisco NCT06105710

Набира участници

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Heart Failure Cognitive Impairment Dementia Left Ventricular Dysfunction +2

This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.

Начало: 01.07.2024 Край: 01.07.2026 Възраст: от 18 г. Превенция

Australia Baker Heart and Diabetes Institute NCT06088212

Набира участници

National Robotics-Assisted Radical Prostatectomy Database

Database Prostate Cancer Robotic-assisted Radical Prostatectomy Surgical Outcomes +3

In Australia, nearly 70 men are diagnosed with Prostate cancer every day. Prostate removal (Radical Prostatectomy) is the proven treatment option to control cancer spread. Most of the prostate removal surgeries are done using robots. Robotic assisted prostate removal surgeries have been invented to minimise the risk of side effects post-surgery. Doctors prefer the robots over open surgery as there are benefits to patients (shorter hospital stays, lesser blood loss and better quality of life) and surgeons (better dexterity, improved field of vision and less pain). However, the cost of the robot outweighs the benefits at present and there is very less information concerning the long-term outcomes for patients. Studies conducted so far are small scale studies and the results from these studies cannot be generalized to the population at large in Australia. So, there is need for a largescale study that will look at the long-term outcomes and the factors that impact robotic surgeries across the metropolitan and rural hospital sectors. Hence, this comprehensive database has been setup to collaborate with major hospitals, across metropolitan and rural areas in Australia. Through this database, researchers will be able to explore the diagnostic pathway for Prostate cancer and understand the long-term benefits of robotic surgery through patient reported questionnaires. Outcomes from this database will also help compare the quality of care against other powerhouses of robotic surgery. Eventually, the database aims to standardize diagnostic pathways and clinical notes that are the same across different hospitals conducting robotic-assisted surgeries for Prostatectomy and improve care for prostate cancer patients across the country.

Начало: 01.07.2024 Край: 01.12.2050 Възраст: 18–90 г.

Australia Melbourne Health NCT06279260

Набира участници Фаза 3

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

Начало: 29.06.2024 Край: 20.08.2027 Възраст: 18–70 г. Лечение

Argentina, Australia, Belgium +27 AstraZeneca NCT06015737

Набира участници

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

Atrial Fibrillation

The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.

Начало: 28.06.2024 Край: 30.06.2026 Възраст: 18–80 г. Лечение

Australia, United States Biosense Webster, Inc. NCT06455098

Набира участници

BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

Idiopathic Intracranial Hypertension (IIH)

1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments. 2. To establish the BMI at which this disease occurs. 3. To establish how much the BMI must be reduced to cure this disease. 4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion

Начало: 27.06.2024 Край: 01.05.2028 Възраст: от 18 г.

Spain University of Valencia NCT06913712

Набира участници Фаза 1

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Breast Cancer Relapse Resistant Cancer Triple Negative Breast Cancer

This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

Начало: 27.06.2024 Край: 01.05.2028 Възраст: от 18 г.

United States UNC Lineberger Comprehensive Cancer Center NCT06347068

Набира участници

Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)

Avoidant/Restrictive Food Intake Disorder (ARFID)

CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID). The purpose of this evaluation is to determine the feasibility, acceptability and effectiveness of this treatment. It is hypothesised that this treatment will be feasible and acceptable to clinicians, carers and patients and will be effective in reducing symptoms of ARFID for patients.

Начало: 27.06.2024 Край: 27.06.2027 Възраст: 12–25 г. Лечение

Australia Orygen NCT06463470

Набира участници Фаза 1

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Pancreatic Ductal Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.

Начало: 27.06.2024 Край: 18.01.2029 Възраст: от 18 г.

China, Puerto Rico, United States Pfizer NCT06447662

Набира участници

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

Uncontrolled Asthma

This study is a multi-centre, non-interventional, observational, ambispective registry. Planned study population consists of 9 000 adult patients with uncontrolled asthma receiving treatment according to standard of care (except biologics). Planned number of study site is 70 outpatient centers with experience of uncontrolled asthma treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled asthma in different regions in the most comprehensive way).

Начало: 27.06.2024 Край: 30.09.2026

Russia AstraZeneca NCT06521229

1 … 134 135 136 137 138 … 222